Loading stock data…
LNTH
$104.52+0.20 (+0.19%)
Pre-Market$104.52+0.00 (+0.00%)· Last close Jun 12
Lantheus Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantheus Holdings, Inc. in the Healthcare sector is trading at $104.52. Wall Street consensus targets $105.23 (13 analysts), implying a +0.7% move over the next 12 months. The stock is currently near its 52-week high of $104.57, remaining 49.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $377.33M↓ | $406.79M↑ | $384.01M↑ | $378.05M↑ | $372.76M |
| Gross Profit | $230.92M↓ | $240.88M↑ | $222.37M↓ | $241.01M↑ | $237.70M |
| Operating Income | $81.33M↑ | $77.18M↑ | $43.62M↓ | $87.97M↓ | $106.79M |
| Net Income | $118.42M↑ | $54.09M↑ | $27.77M↓ | $78.75M↑ | $72.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultras...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.02%
Volume
Today's trading volume
687,504
Recent News
3 Healthcare Stocks with Open Questions
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 6.4% over the past six months, almost identical to the S&P 500.
1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains
Recent performance and context for Lantheus Holdings (LNTH) Lantheus Holdings (LNTH) has attracted investor attention after a recent stretch of strong share performance, with the stock up about 20% over the past month and roughly 42% in the past 3 months. See our latest analysis for Lantheus Holdings. At a share price of US$102.82, Lantheus Holdings has built clear momentum recently, with strong multi month share price returns sitting alongside a 1 year total shareholder return of 28% and a...
Why This Fund Cashed Out of a Stock That Soared 250% in Just One Year
This energy services provider delivers drilling, technology, and equipment solutions to oil and gas clients across more than 20 countries.
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
May 22 () - Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday, citing people familiar with the matter. The two companies have been in discussions about a potential deal that could be weeks away, the report said, adding that no final decision has been made and there is no guarantee the talks will result in a transaction.